New hope for older leukemia patients: gentler Two-Drug combo trial launches
NCT ID NCT07313852
Summary
This study is testing whether combining two targeted drugs, inotuzumab and blinatumomab, is a safe and effective first treatment for adults with a type of blood cancer called B-cell acute lymphoblastic leukemia (B-ALL). It is specifically for patients aged 55 and older, or younger adults who are too frail for standard intensive chemotherapy. The main goal is to see if this combination can put the cancer into deep remission by clearing it from the blood and bone marrow.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.